DFTX · Definium Therapeutics, Inc. · Financials
Market Cap
$5.14B
Shares
134.37M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$183.79M
-69.1%
FY2025
Diluted EPS
-$2.06
-33.8%
FY2025
Operating Cash Flow
-$131.56M
-66.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | $4.66M | $1.5M | -$359K | -$164K | — | |
| $154.65M | $117.67M | $65.3M | $52.12M | $36.17M | $34.79M | $18.63M | — | |
| $72.9M | $48.64M | $38.62M | $41.74M | $30.16M | $59.07M | $14.4M | — | |
| — | $0 | $527K | $3.16M | $3.18M | $2.62M | $0 | — | |
| $227.54M | $166.31M | $103.92M | $93.87M | $66.33M | $93.85M | $33.03M | — | |
| -$227.54M | -$166.31M | -$103.92M | -$93.87M | -$66.33M | -$93.85M | -$33.03M | — | |
| $5.02M | $5.48M | $2.28M | $920K | — | — | — | — | |
| -$126.24M | -$17.48M | -$4.76M | -$1.87M | $9.54M | -$339K | -$907K | — | |
| — | -$183.79M | -$108.68M | -$95.73M | -$56.8M | -$94.19M | -$33.94M | -$10.7M | |
| — | $0 | — | — | — | -$1.16M | — | — | |
| -$353.79M | -$183.79M | -$108.68M | -$95.73M | -$56.8M | -$93.04M | -$33.94M | — | |
| -$353.79M | -$183.79M | -$108.68M | — | — | — | — | — | |
| -$354.18M | -$183.53M | -$108.2M | -$96.02M | -$57.22M | -$92.27M | -$33.65M | — | |
| USD/shares | -$3.44 | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | — | — |
| USD/shares | -$3.36 | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | — | — |
| shares | — | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M | 17.75M | — |
| shares | — | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M | 17.75M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 9.01×
EV/EBIT
—
Peer median 26.76×
P/E (TTM)
—
Peer median 20.00×
Peer medians compare against the 193 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1813814
CUSIP
24477V105
13F (30d)
237 filings
237 filers
Visit website
Investor relations